论文部分内容阅读
2020年中国干眼专家共识完善了干眼的定义和分类，仍将泪膜稳定性异常作为干眼的核心，并保留了泪膜成分异常的分类。地夸磷索钠是一种P2Yn 2受体激动剂，是一种干眼治疗的新药物。地夸磷索钠滴眼液可促进黏蛋白、水液、脂质的分泌，同时改善泪膜各层成分，全面提高泪膜稳定性；其还具有角膜上皮修复作用，因此可用于治疗干眼引起的眼表损伤；针对参与干眼发病机制中的炎症环节，其可以抑制炎症通路和炎性因子的表达。目前已有多中心临床试验证明了地夸磷索钠滴眼液治疗干眼的优势和有效性，亚洲干眼共识将其作为目前水液缺乏型干眼的一线治疗药物，以及治疗黏蛋白缺乏型干眼的首选之一。本文就地夸磷索钠的作用机制、综述其临床应用于不同类型干眼的疗效与安全性、不同泪膜成分异常的干眼治疗以及最新版中国干眼专家共识中的地夸磷索钠的应用，深入了解其在干眼领域治疗的新进展。n “,”Chinese dry eye consensus 2020 updated the definition and classification of dry eye, stressing tear-film instability as the core mechanism of dry eye.The classification criteria are complemented with tear component abnormality as an important category.As a P2Yn 2 receptor agonist, diquafosal sodium is a novel pharmaceutical agent for dry eye treatment.Diquaphosol sodium eye drops can promote the secretion of mucin, fluid and lipid, improve the composition of each layer of tear film, and comprehensively improve the stability of tear film.It also has the function of repairing corneal epithelium, so it can be used to treat ocular surface injury caused by dry eye.Targeting at the inflammation involved in the pathogenesis of dry eye, it can inhibit the inflammatory pathways and the expression of inflammatory factors.The advantages and effectiveness of diquaphosol sodium eye drops in the treatment of dry eye have been demonstrated in multi-center clinical trials, and the Chinese dry eye consensus 2020 has identified diquaphosol sodium eye drops as the first-line treatment for fluid deficient dry eyes and one of the first choices in the treatment of mucin-deficient dry eyes.In this paper, the mechanism, clinical efficacy and safety of diquaphosol sodium in different types of dry eyes, the treatment of different abnormal tear film components and the application of diquaphosol sodium in the Chinese dry eye consensus 2020 were reviewed, so as to deepen its new progress in the treatment of dry eye.n